Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F0434 vs Gabapentin for Diabetic Polyneuropathy
NCT01263132Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2008
- Primary completion
- Feb 2010
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gabapentin + thiamine + cyanocobalamin in diabetic polyneuropathy (DPN) (2 arms), sponsored by Merck KGaA. Primary endpoint: Mean Neuropathic Pain Score at 4 weeks. Started Feb 2008; status: completed.
02
Drugs
gabapentin + thiamine + cyanocobalamin
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT01263132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01263132.